News

Under the deal, Merck’s subsidiary will purchase all outstanding shares of Peloton in exchange for an upfront payment of $1.05bn (£825m) in cash. The shareholders of Peloton will

Patients treated with mirikizumab in the SERENITY Phase 2 study achieved significant reductions in clinical and endoscopic measures of disease activity at 12 weeks compared to placebo. The

Desmoid tumors are rare and often debilitating and disfiguring soft-tissue tumors that can aggressively invade surrounding healthy tissues, including joints, muscles, blood vessels, nerves and internal organs. Depending

The all-cash deal between Catalent and Paragon, which was signed in April 2019, was completed after meeting of customary closing conditions such as the expiration of the waiting

These results are published in the New England Journal of Medicine and are being presented at the American Thoracic Society 2019 International Conference. The trial compared Symbicort Turbuhaler with

In children, SBS is a life-threatening, chronic, and rare malabsorption disorder resulting from surgical removal of a large portion of the intestine, which is typically due to congenital

Under the terms of the agreement, Ligand will receive an upfront license fee, and is eligible to receive over $76 million of milestone payments and tiered royalties in

Depatux-M fails to meet objectives in INTELLANCE-1 study The biopharma company arrived at the decision after finding that the late-stage INTELLANCE-1 study did not meet primary endpoint of

The Cork site will expand capacity to meet customer demand for the development and commercial manufacturing of complex active pharmaceutical ingredients (APIs). With more than 400 employees, the